The drug company GlaxoSmithKline hopes that making its research available to scientists will lead to safer, more effective drugs. Whether more disclosure might lead to safer, more effective drugs remains to be seen. GlaxoSmithKline, a British drug concern, will open its clinical trial data to other researchers once a drug has completed the approval process or been abandoned. Glaxo is taking the step after experimenting with disclosure for treatments for tropical diseases like malaria and finding those efforts successful, according to company officials. In addition, the company plans to release information about 200 of its experimental drug compounds that have shown signs of fighting tuberculosis. Learn more by clicking on the image or the title.